Pharmacokinetics and pharmacodynamics of a new reformulated microemulsion and the long-chain triglyceride emulsion of propofol in beagle dogs

British Journal of Pharmacology

Volumn 158, Issue 8, 2009, Pages 1982-1995

  Lee, S H ^a   Ghim, J L ^a   Song, M H ^b   Choi, H G ^a   Choi, B M ^c   Lee, H M ^b   Lee, E K ^d   Roh, Y J ^e   Noh, G J ^a,b  

^a University of Ulsan   (South Korea)

^b Yeungnam University Hospital   (South Korea)

^c National Medical Center   (South Korea)

^d Ewha Womans University   (South Korea)

^e Seoul National University Boramae Hospital   (South Korea)

Author keywords

Dog; EEG; Microemulsion; Pharmacodynamics; Pharmacokinetics; Propofol

Indexed keywords

LONG CHAIN TRIACYLGLYCEROL; PROPOFOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CONTROLLED STUDY; DOG; DRUG FORMULATION; ELECTROENCEPHALOGRAM; ENTROPY; FEMALE; MALE; MEAN ARTERIAL PRESSURE; MICROEMULSION; NONHUMAN; PRIORITY JOURNAL;

ANESTHETICS, INTRAVENOUS; ANIMALS; AREA UNDER CURVE; BODY WEIGHT; CROSS-OVER STUDIES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; EMULSIONS; ENTROPY; FEMALE; MALE; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROPOFOL; RANDOM ALLOCATION; THERAPEUTIC EQUIVALENCY; TISSUE DISTRIBUTION; TRIGLYCERIDES;

EID: 71649115735     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00509.x     Document Type: Article

References (37)

1. Beal S, Sheiner L (1992). NONMEM User's Guides Part V Introductory Guide. NONMEM Project Group, University of California: San Francisco, CA.
2. Beths T, Glen JB, Reid J, Monteiro AM, Nolan AM (2001). Evaluation and optimisation of a target-controlled infusion system for administering propofol to dogs as part of a total intravenous anaesthetic technique during dental surgery. The Veterinary Rec 148: 198 203.
3. Booles D, Poore DW, Legrand-Defretin V, Burger IH (1994). Body composition of male and female Labrador retriever puppies at 20 wk of age. J Nutr 124: 2624S 2625S.
4. Bruhn J, Bouillon TW, Hoeft A, Shafer SL (2002). Artifact robustness, inter-and intraindividual baseline stability, and rational EEG parameter selection. Anesthesiology 96: 54 59.
5. Cockshott ID, Douglas EJ, Plummer GF, Simons PJ (1992). The pharmacokinetics of propofol in laboratory animals. Xenobiotica; the fate of foreign compounds in biol systems 22: 369 375.
6. CTEP (2006). Common Terminology Criteria for Adverse Events (CTCAE) v3.0. Bethesda: Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute (NCI), U.S. National Institutes of Health, NIH).
7. Devlin JW, Lau AK, Tanios MA (2005). Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy 25: 1348 1352.
8. Dutta S, Ebling WF (1997). Emulsion formulation reduces propofol's dose requirements and enhances safety. Anesthesiology 87: 1394 1405.
9. Dutta S, Ebling WF (1998). Formulation-dependent pharmacokinetics and pharmacodynamics of propofol in rats. J Pharm Pharmacol 50: 37 42. (Pubitemid 28052518)
10. EMEA (2008). Guideline on the Investigation of Bioequivalence. European Agency for the Evaluation of Medical Products (EMEA): London.
11. FDA (2001). Guidance for Industry: Statistical Approaches to Establishing Bioequivalence. US Food and Drug Administration (FDA): Rockville.
12. Franks NP (2006). Molecular targets underlying general anaesthesia. Br J Pharmacol 147: S72 81.
13. Grindel JM, Jaworski T, Emanuele RM, Culbreth P (2002a). Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man. Biopharm Drug Dispos 23: 87 103. (Pubitemid 34467482)
14. Grindel JM, Jaworski T, Piraner O, Emanuele RM, Balasubramanian M (2002b). Distribution, metabolism, and excretion of a novel surface-active agent, purified poloxamer 188, in rats, dogs, and humans. J Pharm Sci 91: 1936 1947.
15. Haskins SC (1996). Monitoring the anesthetized patient. In: Thurmon JC, Tranquilli WJ, Benson GJ (eds). Veterinary Anesthesia, 3rd edn. Williams & Wilkins: Baltimore, MD, p. 418.
16. Hicks CR, Turner VT (1999). Nested and nested-factorial experiments. In: Hicks CR, Turner VT (eds). Fundamental Concepts in the Design of Experiments, 5th edn. Oxford University Press: New York, pp. 190 221.
17. Holford NH, Sheiner LB (1981). Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 6: 429 453.
18. Hooker AC, Staatz CE, Karlsson MO (2007). Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24: 2187 2197.
19. Hummel J, McKendrick S, Brindley C, French R (2008). Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 8: 38 49.
20. Jonsson EN, Karlsson MO (1999). Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58: 51 64.
21. Kang SH, Poynton MR, Kim KM, Lee H, Kim DH, Lee SH et al. (2007). Population pharmacokinetic and pharmacodynamic models of remifentanil in healthy volunteers using artificial neural network analysis. British J Clin pharmacology 64: 3 13.
22. Karlsson MO, Savic RM (2007). Diagnosing model diagnostics. Clin Pharmacol Ther 82: 17 20.
23. Kim KM, Choi BM, Park SW, Lee SH, Christensen LV, Zhou J et al. (2007). Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion. Anesthesiology 106: 924 934.
24. Lee EH, Lee SH, Park DY, Ki KH, Lee EK, Lee DH et al. (2008). Physicochemical properties, pharmacokinetics, and pharmacodynamics of a reformulated microemulsion propofol in rats. Anesthesiology 109: 436 447.
25. Lindbom L, Pihlgren P, Jonsson EN (2005). PsN-Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comp methods and programs in biomedicine 79: 241 257.
26. Minto CF, Schnider TW (2008). Contributions of PK/PD modeling to intravenous anesthesia. Clin Pharmacol Ther 84: 27 38.
27. Morey TE, Modell JH, Shekhawat D, Grand T, Shah DO, Gravenstein N et al. (2006). Preparation and anesthetic properties of propofol microemulsions in rats. Anesthesiology 104: 1184 1190. (Pubitemid 43852951)
28. Noh GJ, Kim KM, Jeong YB, Jeong SW, Yoon HS, Jeong SM et al. (2006). Electroencephalographic approximate entropy changes in healthy volunteers during remifentanil infusion. Anesthesiology 104: 921 932.
29. Nolan A, Reid J (1993). Pharmacokinetics of propofol administered by infusion in dogs undergoing surgery. Br J Anaesth 70: 546 551.
30. Park JW, Park ES, Chi SC, Kil HY, Lee KH (2003). The effect of lidocaine on the globule size distribution of propofol emulsions. Anesth Analg 97: 769 771.
31. Parke J, Holford NH, Charles BG (1999). A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 59: 19 29.
32. Pellegrino FC, Sica RE (2004). Canine electroencephalographic recording technique: findings in normal and epileptic dogs. Clin Neurophysiol 115: 477 487.
33. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL et al. (1998). The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology 88: 1170 1182.
34. Schuttler J, Kloos S, Schwilden H, Stoeckel H (1988). Total intravenous anaesthesia with propofol and alfentanil by computer-assisted infusion. Anaesthesia 43: 2 7.
35. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25: 358 371.
36. Takizawa Y, Nishimura H, Morota T, Tomisawa H, Takeda S, Aburada M (2004). Pharmacokinetics of TJ-8117 (Onpi-to), a drug for renal failure (I): Plasma concentration, distribution and excretion of [3H]-(-)epicatechin 3-O-gallate in rats and dogs. Eur J Drug Metab Pharmacokinet 29: 91 101.
37. Yamakage M, Iwasaki S, Satoh J, Namiki A (2005). Changes in concentrations of free propofol by modification of the solution. Anesth Analg 101: 385 388, table of contents.